EGFR and non-small cell lung carcinoma: In addition, the T790M ratio was significantly associated with PFS in de novo T790M+ NSCLC patients treated with EGFR‐TKIs, implying that a subclone of T790M mutation tumors influenced the response to EGFR‐TKIs.